The Latest Cardiac and Vascular News
Highly specific HDAC6 inhibitors (HDAC6i) demonstrated improved cardiac function in mouse models of heart failure with preserved ejection in fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM) Potential utility of HDAC6 as a target in heart disease was validated using Tenaya’s Precision Medicine platform HDAC6i product candidate TYA-11631 is currently in IND-enabling […]
Series C round led by RTW Investments, LP; RA Capital Management; Fidelity Management & Research Company; and funds and accounts advised by T. Rowe Price Associates, Inc.; and joined by existing investors including The Column Group, Casdin Capital and GV. Funds will help advance lead gene therapy program in hypertrophic […]
SOUTH SAN FRANCISCO, Calif., July 30, 2018 /PRNewswire/ — Tenaya Therapeutics, a preclinical-stage biotechnology company focused on discovery and development of novel therapies for heart failure, announced the appointment of Faraz Ali as Chief Executive Officer. “We are thrilled to bring Faraz on board as the new CEO,” said David Goeddel, Ph.D., Managing Partner at The […]
